The Filing Desk

Aligos Therapeutics vs Humacyte

Aligos Therapeutics ALGS · Humacyte HUMA · Biotechnology

Aligos Therapeutics reported revenue of $2 million in fiscal 2025, about the same as Humacyte's $2 million in fiscal 2025. Aligos Therapeutics had an operating margin of -4024.9%, against -5306.0% at Humacyte.

Side by side

Aligos TherapeuticsHumacyte
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$2M
Revenue growth−39.5%—
Revenue growth a year, last 5 years——
Gross margin—−376.1%
Operating margin−4,024.9%−5,306.0%
Net margin−1,106.7%−2,003.6%
Free cash flow—−$106M
Free cash flow margin—−5,197.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count57.8%33.5%
Last close$1.25$0.54
P/E at the last close——
Insider trades, last 12 months—bought $89,990, sold $41,298
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aligos TherapeuticsHumacyte
Operating margin
Percent of revenue
Aligos TherapeuticsHumacyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aligos TherapeuticsHumacyte

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aligos Therapeutics and Humacyte pages.